Duke-NUS Medical School
Dr. Antonio Bertoletti, MD, is a leading expert in viral hepatitis and T-cell based immunotherapies. With a distinguished career spanning decades, Dr. Bertoletti has made significant contributions to understanding the immunopathogenesis of Hepatitis B virus (HBV) infection. He pioneered the characterization of HBV-specific cytotoxic T cell responses in humans during his time at The Scripps Research Institute. He has held prominent positions at institutions including the University of Parma, the MRC Unit in the Gambia, and the UCL Institute of Hepatology. In 2006, he moved to Singapore, serving as Director of the Infection and Immunity Program at the Singapore Institute for Clinical Sciences (A*STAR) and later as Full Professor at Duke-NUS Medical School. Dr. Bertoletti is a pioneer in developing T cell receptor (TCR) engineered T cell therapies for virus-related cancers and chronic viral infections. He founded Lion TCR Pte, a biotech company that has conducted groundbreaking clinical trials for HBV-related hepatocellular carcinoma (HCC). His current research focuses on advancing immunological therapies for HBV and HCC, and he has also made significant contributions to understanding SARS-CoV-2 specific T cell responses during the COVID-19 pandemic. Dr. Bertoletti’s expertise and leadership make him an invaluable advisor in the field of T cell-based therapies.
Qualification
PhD
Title and Affiliation
Professor, Signature Research Programme in Emerging Infectious Diseases
Duke-NUS Graduate Medical School
Brief Description of Collaboration
Dr. Antonio Bertoletti, MD, is a leading expert in viral hepatitis and T-cell based immunotherapies.
With a distinguished career spanning decades, Dr. Bertoletti has made significant contributions to understanding the immunopathogenesis of Hepatitis B virus (HBV) infection. He pioneered the characterization of HBV-specific cytotoxic T cell responses in humans during his time at The Scripps Research Institute.
He has held prominent positions at institutions including the University of Parma, the MRC Unit in the Gambia, and the UCL Institute of Hepatology. In 2006, he moved to Singapore, serving as Director of the Infection and Immunity Program at the Singapore Institute for Clinical Sciences (A*STAR) and later as Full Professor at Duke-NUS Medical School.
Dr. Bertoletti is a pioneer in developing T cell receptor (TCR) engineered T cell therapies for virus-related cancers and chronic viral infections. He founded Lion TCR Pte, a biotech company that has conducted groundbreaking clinical trials for HBV-related hepatocellular carcinoma (HCC).
His current research focuses on advancing immunological therapies for HBV and HCC, and he has also made significant contributions to understanding SARS-CoV-2 specific T cell responses during the COVID-19 pandemic.
Dr. Bertoletti's expertise and leadership make him an invaluable advisor in the field of T cell-based therapies.
Email: [email protected]
Link: https://www.duke-nus.edu.sg/directory/detail/antonio-bertoletti